Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Fabry disease: is there a role for enzyme replacement therapy?

Mehta AB.

J Intern Med. 2013 Oct;274(4):329-30. doi: 10.1111/joim.12089. Epub 2013 May 30. No abstract available.

2.

Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications.

Weidemann F, Niemann M, Störk S, Breunig F, Beer M, Sommer C, Herrmann S, Ertl G, Wanner C.

J Intern Med. 2013 Oct;274(4):331-41. doi: 10.1111/joim.12077. Epub 2013 May 6.

3.

Fabry disease: dose matters.

Warnock DG, Mauer M.

J Am Soc Nephrol. 2014 Apr;25(4):653-5. doi: 10.1681/ASN.2013121322. Epub 2014 Feb 20. No abstract available.

4.

Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.

Cybulla M, Kurschat C, West M, Nicholls K, Torras J, Sunder-Plassmann G, Feriozzi S.

J Nephrol. 2013 Jul-Aug;26(4):645-51. doi: 10.5301/jn.5000214. Epub 2012 Sep 19. Review.

PMID:
23023720
5.

Beneficial effects of long-term enzyme replacement therapy in a child with Fabry disease.

Martin-Suárez I, Suárez-Marrero C.

Int J Clin Pract. 2010 Jun;64(7):995. doi: 10.1111/j.1742-1241.2009.02323.x. No abstract available.

PMID:
20584233
6.

Diagnosis and management of kidney involvement in Fabry disease.

Warnock DG, West ML.

Adv Chronic Kidney Dis. 2006 Apr;13(2):138-47. Review. Erratum in: Adv Chronic Kidney Dis. 2006 Oct;13(4):433. Dosage error in article text.

PMID:
16580615
7.

Enzyme replacement therapy for Fabry's disease.

Waldek S, Germain DP, Wanner C, Warnock DG.

Lancet. 2010 May 1;375(9725):1523; author reply 1523-4. doi: 10.1016/S0140-6736(10)60653-8. No abstract available.

PMID:
20435225
8.

Enzyme replacement therapy for Fabry's disease.

Deegan P.

Lancet. 2010 May 1;375(9725):1522-3; author reply 1523-4. doi: 10.1016/S0140-6736(10)60652-6. No abstract available.

PMID:
20435224
9.

Treatment with agalsidase beta during pregnancy in Fabry disease.

Politei JM.

J Obstet Gynaecol Res. 2010 Apr;36(2):428-9. doi: 10.1111/j.1447-0756.2009.01164.x.

PMID:
20492401
10.

Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al.

Linthorst GE, Aerts JM.

J Inherit Metab Dis. 2011 Feb;34(1):237-8. doi: 10.1007/s10545-010-9219-y. Epub 2010 Oct 12. No abstract available.

11.

[Enzyme therapy in Fabry disease: when scarcity of one enzyme illustrates the vulnerability of biotech].

Lidove O, Choukroun G, Bekri S, Viot G, Tsimaratos M, Joly D.

Presse Med. 2010 May;39(5):527-9. doi: 10.1016/j.lpm.2010.01.002. Epub 2010 Mar 2. French. No abstract available.

PMID:
20194001
12.

Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.

Senocak Tasci E, Bicik Z.

Iran J Kidney Dis. 2015 Sep;9(5):406-8.

13.

Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?

Fauchais AL, Prey S, Ouatara B, Vidal E, Sparsa A.

J Eur Acad Dermatol Venereol. 2010 Jun;24(6):737-8. doi: 10.1111/j.1468-3083.2009.03455.x. Epub 2009 Nov 11. No abstract available.

PMID:
19925601
14.

Reduction in ECG abnormalities and improvement of regional left ventricular function in a patient with Fabry's disease during enzyme-replacement therapy.

Prinz C, Farr M, Hering D, Horstkotte D, Faber L.

Clin Res Cardiol. 2010 Jan;99(1):53-5. doi: 10.1007/s00392-009-0084-3. Epub 2009 Sep 23. No abstract available.

PMID:
19774328
15.

Enzyme replacement in Fabry disease: the essence is in the kidney.

Schiffmann R.

Ann Intern Med. 2007 Jan 16;146(2):142-4. Epub 2006 Dec 18. No abstract available.

PMID:
17179053
16.

Update on role of agalsidase alfa in management of Fabry disease.

Ramaswami U.

Drug Des Devel Ther. 2011 Mar 14;5:155-73. doi: 10.2147/DDDT.S11985. Review.

17.

Do we need more intensive enzyme replacement therapy for Anderson-Fabry disease?

Basic-Jukic N, Kes P, Mokos I, Coric M.

Med Hypotheses. 2009 Apr;72(4):476-7. doi: 10.1016/j.mehy.2008.11.021. Epub 2009 Jan 4. No abstract available.

PMID:
19124204
18.

Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.

Mehta A, Beck M, Kampmann C, Frustaci A, Germain DP, Pastores GM, Sunder-Plassmann G.

Mol Genet Metab. 2008 Sep-Oct;95(1-2):114-5. doi: 10.1016/j.ymgme.2008.07.002. Epub 2008 Aug 12. No abstract available.

PMID:
18701330
19.

The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.

Morel CF, Clarke JT.

Expert Opin Biol Ther. 2009 May;9(5):631-9. doi: 10.1517/14712590902902296 . Review.

PMID:
19368525
20.

[Utility of enzyme replacement therapy in Fabry disease].

Politei JM, Dubrovsky A.

Med Clin (Barc). 2010 Apr 3;134(9):402-5. doi: 10.1016/j.medcli.2009.07.053. Epub 2010 Feb 6. Spanish.

PMID:
20138313

Supplemental Content

Support Center